Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon^® and Eprex^® following a single subcutaneous administration in healthy male volunteers

References

• TsagalisGRenal anemia: a nephrologist’s viewHippokratia201115Suppl 1 39 4321897757
   PubMed Web of Science ®Google Scholar
• BabittJLLinHYMechanisms of anemia in CKDJ Am Soc Nephrol20122310 1631 163422935483
   PubMed Web of Science ®Google Scholar
• KligerASFishbaneSFinkelsteinFOErythropoietic stimulating agents and quality of a patient’s life: individualizing anemia treatmentClin J Am Soc Nephrol201272 354 35722266571
   PubMed Web of Science ®Google Scholar
• Martinez-CastelaoACasesACarballadaATinvestigators of the ACERCA Study GroupClinical impact of the ERBP working group 2010 recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA studyNefrologia2015352 179 18826300512
   PubMed Web of Science ®Google Scholar
• KDIGO Anemia Work GroupKDIGO clinical practice guideline for anemia in chronic kidney diseaseKidney Int Suppl201224 279 335
   Google Scholar
• Kalantar-ZadehKHistory of erythropoiesis-stimulating agents, the development of biosimilars, and the future of anemia treatment in nephrologyAm J Nephrol2017453 235 24728142147
   PubMed Web of Science ®Google Scholar
• StorringPLTipladyRJGaines DasREEpoetin alfa and beta differ in their erythropoietin isoform compositions and biological propertiesBr J Haematol19981001 79 899450795
   PubMed Web of Science ®Google Scholar
• Aranesp^® (Darbepoetin alfa) [package insert]Thousand Oaks, CAAmgen Inc2016
   Google Scholar
• YuSKangCKangKLeeHNohHShinSPhase III clinical study of recombinant human erythropoietin (Eporon®) on anemia of chronic renal failureKorean J of Nephrol2000196 1053 1062
   Google Scholar
• Epogen^® (Epoetin alfa) [package insert]Thousand Oaks, CAAmgen Inc2014
   Google Scholar
• YanXLowePJFinkMBerghoutABalserSKrzyzanskiWPopulation pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575J Clin Pharmacol20125211 1624 164422162538
   PubMed Web of Science ®Google Scholar
• GermainMRamCVBhaduriSTangKLKlausnerMCurziMExtended epoetin alfa dosing in chronic kidney disease patients: a retrospective reviewNephrol Dial Transplant20052010 2146 215215985516
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER)Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product2016
   Google Scholar
• World Medical AssociationDeclaration of Helsinki: ethical principles for medical research involving human subjectsJAMA201331020 2191 219424141714
   PubMed Web of Science ®Google Scholar
• ICH Expert Working GroupGuideline for Good Clinical Practice E6 (R1)1996 Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guide-line.pdfAccessed May 01, 2017
   Google Scholar
• SorgelFThyroff-FriesingerUVetterAVens-CappellBKinzigMBioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrationsPharmacology2009832 122 13019122476
   PubMed Web of Science ®Google Scholar
• RamakrishnanRCheungWKWacholtzMCMintonNJuskoWJPharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteersJ Clin Pharmacol2004449 991 100215317827
   PubMed Web of Science ®Google Scholar
• Veng-PedersenPWidnessJAPereiraLMPetersCSchmidtRLLoweLSKinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humansJ Pharm Sci1995846 760 7677562419
   PubMed Web of Science ®Google Scholar
• PeletierLAGabrielssonJDynamics of target-mediated drug disposition: characteristic profiles and parameter identificationJ Pharmacokinet Pharmacodyn2012395 429 45122851162
   PubMed Web of Science ®Google Scholar
• HalstensonCEMacresMKatzSAComparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin betaClin Pharmacol Ther1991506 702 7121752115
   PubMed Web of Science ®Google Scholar
• HanHLeeJShinDPharmacodynamics, pharmacokinetics, and tolerability of intravenous or subcutaneous GC1113, a novel erythropoiesis-stimulating agentClin Drug Investig2014346 373 382
   Web of Science ®Google Scholar
• TsitsimpikouCKouretasDTsarouhasKFitchKSpandidosDATsatsakisAApplications and biomonitoring issues of recombinant erythropoietins for doping controlTher Drug Monit2011331 3 1321099742
   PubMed Web of Science ®Google Scholar
• FlahartyKKClinical pharmacology of recombinant human erythropoietin (r-HuEPO)Pharmacotherapy1990102 S9 S14
   Web of Science ®Google Scholar
• European Medicines Agency (EMA) Committee for Medicinal Products for Human UseGuideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision)2010
   Google Scholar
• Ministry of Food and Drug SafetyGuideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins2011
   Google Scholar
• PocockSJAshbyDShaperAGWalkerMBroughtonPMDiurnal variations in serum biochemical and haematological measurementsJ Clin Pathol1989422 172 1792921359
   PubMed Web of Science ®Google Scholar
• CheungWKGoonBLGuilfoyleMCWacholtzMCPharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjectsClin Pharmacol Ther1998644 412 4239797798
   PubMed Web of Science ®Google Scholar
• StalkerDRamaiyaAKumbhatSZhangJReidSMartinNPharmacodynamic and pharmacokinetic equivalences of epoetin hospira and epogen((R)) after multiple subcutaneous doses to healthy male subjectsClin Ther2016385 1090 110127112531
   PubMed Web of Science ®Google Scholar
• LissyMOdeMRothKComparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective studyDrugs R D2011111 61 7521410296
   PubMedGoogle Scholar
• GoodnoughLTSkikneBBrugnaraCErythropoietin, iron, and erythropoiesisBlood2000963 823 83310910892
   PubMed Web of Science ®Google Scholar
• SouillardAAudranMBressolleFGareauRDuvalletAChanalJLPharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping controlBr J Clin Pharmacol1996423 355 3648877027
   PubMed Web of Science ®Google Scholar
• RowlandMTozerTNClinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications4th edBaltimore, MD, USAWolters Kluwer Health/Lippincott William & Wilkins2011
   Google Scholar
• KrzyzanskiWJuskoWJWacholtzMCMintonNCheungWKPharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjectsEur J Pharm Sci2005263–4 295 30616102948
   PubMed Web of Science ®Google Scholar
• MacdougallICCasadevallNLocatelliFPRIMS study groupIncidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)Nephrol Dial Transplant2015303 451 46025239637
   PubMed Web of Science ®Google Scholar
• CasadevallNNatafJVironBPure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietinN Engl J Med20023467 469 47511844847
   PubMed Web of Science ®Google Scholar
• VerhelstDRossertJCasadevallNKrugerAEckardtKUMacdougallICTreatment of erythropoietin-induced pure red cell aplasia: a retrospective studyLancet20043639423 1768 177115172775
   PubMed Web of Science ®Google Scholar
• McKoyJMStonecashRECournoyerDEpoetin-associated pure red cell aplasia: past, present, and future considerationsTransfusion2008488 1754 176218482185
   PubMed Web of Science ®Google Scholar